Truist Boosts Teva (TEVA) Stock Target Amid Pipeline Growth Opportunities

Teva Pharmaceutical Industries Limited (NYSE:TEVA) ranks among billionaire Stanley Druckenmiller’s 10 best stock picks. Truist Securities boosted Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s price target to $38 from $36 on January 28, retaining a Buy rating for the pharma company. The revision comes after Teva’s Q4 2025 results that featured a one-time $500 million Duvakitug Phase 3 landmark contribution. Truist emphasized that the upcoming enactment of the Inflation Reduction Act and recent inve ...